Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 33 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

55%

18 trials in Phase 3/4

Results Transparency

10%

2 of 21 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 4

10(38.5%)

Phase 3

8(30.8%)

Phase 2

4(15.4%)

Phase 1

3(11.5%)

N/A

1(3.8%)

26Total

Phase 4(10)

Phase 3(8)

Phase 2(4)

Phase 1(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials

NCT07525245Not ApplicableNot Yet Recruiting

Effectiveness of Large Language Model-Based Chatbot Among Parents of Junior High School Girls in Improving Human Papillomavirus (HPV) Vaccine Awareness, Intention and Vaccination Rates

Role: collaborator

NCT04537156Phase 3Active Not Recruiting

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Role: collaborator

NCT06243666Active Not Recruiting

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Role: collaborator

NCT06197802Active Not Recruiting

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

Role: collaborator

NCT06866574Phase 3Active Not Recruiting

A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males

Role: collaborator

NCT05056402Phase 3Active Not Recruiting

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

Role: collaborator

NCT06306196Phase 2Recruiting

Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children

Role: collaborator

NCT06824896Completed

A Post-marketing Observational Database Study Monitoring the Safety of CecolinⓇ

Role: lead

NCT04508309Phase 3Completed

Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls

Role: collaborator

NCT06564116Phase 4Completed

Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above

Role: lead

NCT06345885Phase 4Completed

Immunogenicity and Safety of One Dose of HPV Vaccine

Role: lead

NCT02710851Phase 2Unknown

Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

Role: collaborator

NCT04782895Phase 3Completed

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

Role: collaborator

NCT04704908Unknown

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)

Role: collaborator

NCT05045755Unknown

The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Role: collaborator

NCT04969445Unknown

The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Role: collaborator

NCT05426148Phase 4Completed

Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

Role: lead

NCT05415345Phase 4Unknown

Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

Role: lead

NCT02405520Phase 1Completed

Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

Role: collaborator

NCT03935204Phase 2Completed

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Role: collaborator